-
Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations
•
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced the decision to wind down two of its subsidiaries, Zhejiang Raybow Life Science Technology Co., Ltd and Raybow Europe Incorporated ApS. This strategic move aims to optimize resource allocation, reduce management costs, and enhance operational…
-
Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary
•
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans to invest USD 9.5 million in the establishment of a wholly-owned subsidiary in Germany that will provide Contract Research Organization (CRO) services. The new unit, temporarily named Jiuzhou Pharma Europe GmbH, is anticipated to be…
-
Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services
•
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to invest USD 42 million in the establishment of a wholly-owned subsidiary in Japan that will offer Contract Research Organization (CRO) services. This strategic expansion will be executed through Jiuzhou’s existing wholly-owned subsidiary, Raybow Life Sciences（Singapore）Pte…
